Nivolumab increases pulmonary artery pressure in patients treated for non-small cell lung cancer

ConclusionNivolumab is associated to PAD enlargement, a potential marker of pulmonary hypertension, sometimes leading to lethal adverse events. Careful CT-scan and echocardiographic evaluation of PAD should be part of the therapeutic work-up of patients receiving Nivolumab, especially those suffering cancer-associated malnutrition.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research